When might we see human trials of stem cell-based gene therapy in glioblastoma?
We are ready to go, and interested in hearing from any company or foundation or academic institution that wishes to partner with us to get this going quickly. Much of the private sector has not jumped into the stem cell field, for various reasons—some because of the politics, others because clinical translation seems so distant. But gaps in present brain tumor therapy are so consistent with the known properties, capabilities, and techniques of stem cell biology, that there is no question in my mind that this is the low-hanging fruit in the field. We have the potential for helping to satisfy—if even in a small measure—an acute medical need. All we lack now is the funding to give it a shot in a clinical trial.
